23.11.2010 • NewsCollaborationcooperationEvotec

Evotec, Merck KGaA Collaborate on Neurological Disease Target

Evotec has signed an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease. Evotec will provide drug discovery expertise covering in vitro biology, medicinal chemistry and in vitro and in vivo pharmacology.

As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small molecules for the selected target. The molecules will be further optimised and progressed through lead optimization to a pre-clinical candidate.

The cooperation will take place within the "NEU²-Consortium" framework and partially funded by the Federal Ministry of Education and Research.

Company

Evotec

Schnackenburgallee 114
22525 Hamburg
Germany

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.